Immune biomarkers of anti-EGFR monoclonal antibody therapy
about
Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancerSTAT1-Induced HLA Class I Upregulation Enhances Immunogenicity and Clinical Response to Anti-EGFR mAb Cetuximab Therapy in HNC Patients.Targeting epidermal growth factor receptor for head and neck squamous cell carcinoma: still lost in translation?Prognostic and predictive value of EGFR in head and neck squamous cell carcinomaSpotlight on necitumumab in the treatment of non-small-cell lung carcinoma.Biological mechanisms of immune escape and implications for immunotherapy in head and neck squamous cell carcinoma.Urokinase-type plasminogen activator receptor (uPAR), tissue factor (TF) and epidermal growth factor receptor (EGFR): tumor expression patterns and prognostic value in oral cancer.Targeted Therapies: Immunologic Effects and Potential Applications Outside of Cancer.Peripheral White Blood Cell Subsets in Metastatic Colorectal Cancer Patients Treated with Cetuximab: The Potential Clinical Relevance.CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer.Expressional analysis of disease-relevant signalling-pathways in primary tumours and metastasis of head and neck cancers.Necitumumab in squamous non-small-cell lung cancer: how to move forward?Coexpression of p-IGF-1R and MMP-7 Modulates Panitumumab and Cetuximab Efficacy in RAS Wild-Type Metastatic Colorectal Cancer Patients.
P2860
Q35786634-497984C6-701A-4480-A82F-63BEA1447FBCQ35920773-5353A0ED-DF6A-45CF-95CC-1849835E4B65Q36656097-5BD5D32C-A362-495F-B443-AC497976D729Q38935842-2EFD3DC8-C4BC-4BF6-B907-70CE9E23BD54Q39178484-39EC2C77-6585-4B95-9051-8AF919FE4D24Q39190801-F2CB6155-A15A-4BA7-910C-591C56079FABQ41542151-7C7E02DD-379F-4E5B-8127-5231868E1554Q47350013-A4081361-1F78-4518-B075-47CD1D01B981Q49295280-0BB02CB3-6A6E-46AD-8CE3-A5800A5E09C4Q50043038-DFAA12EB-F484-4758-B4FA-0823DFA6FF24Q54979438-C3FB0CB3-1233-4A0B-AB29-825A261A9981Q55020992-33703468-7868-49B7-BAF0-174E2543ACF3Q55518473-3AE79115-F32F-4220-869F-F8443B2EF7D7
P2860
Immune biomarkers of anti-EGFR monoclonal antibody therapy
description
2014 nî lūn-bûn
@nan
2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Immune biomarkers of anti-EGFR monoclonal antibody therapy
@ast
Immune biomarkers of anti-EGFR monoclonal antibody therapy
@en
Immune biomarkers of anti-EGFR monoclonal antibody therapy
@nl
type
label
Immune biomarkers of anti-EGFR monoclonal antibody therapy
@ast
Immune biomarkers of anti-EGFR monoclonal antibody therapy
@en
Immune biomarkers of anti-EGFR monoclonal antibody therapy
@nl
prefLabel
Immune biomarkers of anti-EGFR monoclonal antibody therapy
@ast
Immune biomarkers of anti-EGFR monoclonal antibody therapy
@en
Immune biomarkers of anti-EGFR monoclonal antibody therapy
@nl
P2093
P2860
P356
P1433
P1476
Immune biomarkers of anti-EGFR monoclonal antibody therapy
@en
P2093
F Concha-Benavente
N C Schmitt
R L Ferris
S P Gibson
P2860
P356
10.1093/ANNONC/MDU156
P577
2014-07-04T00:00:00Z